In a groundbreaking development, healthcare startup Qure.ai has secured a substantial $16 million investment to advance its pioneering AI-powered medical solutions.
Back
Qure.ai's game-changing product, qXR, has been lauded for its ability to swiftly and accurately identify markers in chest X-rays. This breakthrough technology holds immense promise for regions with limited access to clinics. This recent infusion of funds will fuel Qure.ai's global expansion plans and facilitate regulatory clearances for their revolutionary offerings.
The visionary co-founder and CEO of Qure.ai, Prashant Warier, expressed immense pride in the company's accomplishments thus far. Qure.ai's solutions have already made a tangible impact in over 200 locations across 20 countries, ensuring that life-saving treatments can be administered promptly, even in remote areas.
By significantly reducing the time required for traditional scan interpretation, Qure.ai's products are set to redefine the future of accessible and affordable healthcare.
Central to qXR's success is an AI model that can analyze chest X-rays in milliseconds, detecting up to 15 common markers, including tuberculosis, COPD, lung malignancies, and specific cardiac disorders.
Qure.ai collated a gallery of over 2.5 million anonymized X-ray images from various medical institutions to train this cutting-edge model, solidifying its position as an industry leader.
Beyond qXR, Qure.ai's comprehensive portfolio includes qER, an AI-powered CT algorithm to identify brain hemorrhages and bone fractures.
By offering cloud-hosted and on-premise installation options, Qure.ai ensures seamless integration into healthcare facilities, granting radiologists access to a state-of-the-art workflow management platform.
The recent funding round was spearheaded by Sequoia India, a testament to Qure.ai's remarkable vision and potential.
MassMutual Ventures Southeast Asia also participated in the investment, further bolstering Qure.ai's position in the healthcare industry. With over 600,000 individuals benefiting from screenings across 20 countries, Qure.ai's impact on global healthcare is poised to accelerate.
